Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor
- PMID: 37108124
- PMCID: PMC10138628
- DOI: 10.3390/ijms24086960
Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor
Abstract
Transplant-associated thrombotic microangiopathy (TMA) occurs in a significant percentage of patients after allogeneic stem cell transplantation (allo-SCT) and is associated with significant morbidity and mortality. The aim of the present study was to examine the association of serum angiopoetin-2 (Ang2) levels and the presence of antibodies against angiotensin II type 1 (AT1R) and ndothelin A Recreptor (ETAR) with the outcome of patients with TMA and/or graft-versus-host disease (GVHD) after allo-SCT. Analysis of our data showed that elevated serum Ang2 levels at the time of TMA diagnosis are significantly associated with increased non-relapse mortality and decreased overall survival. To our knowledge, this is the first study demonstrating an association between raised Ang2 levels and poor outcomes in patients with TMA. Antibodies against AT1R (AT1R-Abs) and ETAR (ETAR-Abs) were detected in 27% and 23% of the patients, respectively, but there was no association between the presence of autoantibodies and the outcome of patients with TMA. However, a significant finding was the strong positive correlation between the presence of AT1R-Abs with the occurrence of chronic fibrotic GVHD, such as scleroderma and cryptogenic organizing pneumonia, raising the possibility of the contribution of autoantibodies in the pathogenesis of fibrotic GVHD manifestations.
Keywords: angiopoetin-2; angiotensin II type 1 receptor; endothelial injury syndromes; endothelin A receptor; graft-versus-host disease; transplant-associated thrombotic microangiopathy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Similar articles
-
Anti-ETAR and anti-AT1R autoantibodies are elevated in patients with endstage cystic fibrosis.J Cyst Fibros. 2015 Jan;14(1):42-5. doi: 10.1016/j.jcf.2014.07.007. Epub 2014 Aug 2. J Cyst Fibros. 2015. PMID: 25096855
-
Non-HLA Autoantibodies Against Angiotensin II Receptor 1 (AT1R) and Endothelin A Receptor (ETAR) in Pediatric Kidney Transplantation.Int J Mol Sci. 2024 Nov 3;25(21):11817. doi: 10.3390/ijms252111817. Int J Mol Sci. 2024. PMID: 39519368 Free PMC article.
-
Non-HLA Autoantibodies at 1 Year Negatively Affect 5-Year Native Renal Function in Liver Transplant Recipients.Transplant Proc. 2021 Apr;53(3):1019-1024. doi: 10.1016/j.transproceed.2021.01.013. Epub 2021 Feb 10. Transplant Proc. 2021. PMID: 33579550
-
Antibodies against Angiotensin II Type 1 and Endothelin 1 Type A Receptors in Cardiovascular Pathologies.Int J Mol Sci. 2022 Jan 15;23(2):927. doi: 10.3390/ijms23020927. Int J Mol Sci. 2022. PMID: 35055116 Free PMC article. Review.
-
Emerging Concepts in Hematopoietic Stem Cell Transplantation-Associated Renal Thrombotic Microangiopathy and Prospects for New Treatments.Am J Kidney Dis. 2018 Dec;72(6):857-865. doi: 10.1053/j.ajkd.2018.06.013. Epub 2018 Aug 23. Am J Kidney Dis. 2018. PMID: 30146419 Review.
Cited by
-
Prognostic role of angiotensin-II receptor type 1 and endothelin-1 receptor type A agonistic autoantibodies in patients with acute myocardial infarction.Front Cardiovasc Med. 2025 Aug 12;12:1515693. doi: 10.3389/fcvm.2025.1515693. eCollection 2025. Front Cardiovasc Med. 2025. PMID: 40873617 Free PMC article.
-
NIH Chronic Graft-Versus-Host Disease Consensus Conference 2025 Update.Transplant Cell Ther. 2025 Sep;31(9):678.e1-678.e16. doi: 10.1016/j.jtct.2025.05.016. Epub 2025 May 21. Transplant Cell Ther. 2025. PMID: 40409691 Review.
References
-
- Tatekawa S., Kohno A., Ozeki K., Watamoto K., Ueda N., Yamaguchi Y., Kobayashi T., Yokota I., Teramukai S., Taniwaki M., et al. A Novel Diagnostic and Prognostic Biomarker Panel for Endothelial Cell Damage–Related Complications in Allogeneic Transplantation. Biol. Blood Marrow Transplant. 2016;22:1573–1581. doi: 10.1016/j.bbmt.2016.05.018. - DOI - PubMed
-
- Ueda N., Chihara D., Kohno A., Tatekawa S., Ozeki K., Watamoto K., Morishita Y. Predictive Value of Circulating Angiopoietin-2 for Endothelial Damage–Related Complications in Allogeneic Hematopoietic Stem Cell Transplantation. Biol. Blood Marrow Transplant. 2014;20:1335–1340. doi: 10.1016/j.bbmt.2014.04.030. - DOI - PubMed
-
- Dietrich S., Falk C.S., Benner A., Karamustafa S., Hahn E., Andrulis M., Hegenbart U., Ho A.D., Dreger P., Luft T. Endothelial Vulnerability and Endothelial Damage Are Associated with Risk of Graft-versus-Host Disease and Response to Steroid Treatment. Biol. Blood Marrow Transplant. 2012;19:22–27. doi: 10.1016/j.bbmt.2012.09.018. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous